Skip to main content

MELanoma GENetics - understanding and biomarking the genetic and immunological determinants of melanoma survival

Objective

MELGEN (MELanoma GENetics) – understanding and biomarking the genetic and immunological determinants of melanoma survival

The MELGEN European Training Network (ETN) will create an environment for long-term, collaborative, inter-sectorial cancer genetics research with the ultimate aim of improving precision (personalised) medicine. In a 2012 report the European Science Foundation identified the importance of precision medicine and recommended that there should be 1) provision of comprehensive, accessible and interoperable datasets 2) improved models and decision-making processes, 3) interdisciplinary, public-private partnerships and translational research, and 4) dedicated funding including access to core technology and frameworks for education and training of professionals. This application addresses all four recommendations and applies them to melanoma. Considerable, but insufficient, progress has been made in understanding the genetic changes within melanomas that drive tumour progression, and how those drivers can be targeted to treat melanoma. Melanoma is also an especially immunogenic cancer and much more needs to be understood of how melanomas suppress host immunological responses. Understanding what controls immunity in melanoma will be potentially applicable to other cancers. Finally, we need prognostic and predictive biomarkers for selection of precision therapy. This ETN will recruit 15 early stage researchers (ESRs) to address these issues. It will bring together leaders in clinical research, genomics, statistics, bioinformatics, and the biotech industry to exploit the new genomic tools and tumour immunology. MELGEN’s commercial partners are developing immunological tests (ImmunID), bioinformatics (Eagle Genomics), commercial genomics (ServiceXS) and digital design/communications (Digitronix) and they will underpin an innovative, interdisciplinary training programme for the next generation of melanoma researchers.

Coordinator

UNIVERSITY OF LEEDS
Net EU contribution
€ 819 863,64
Address
Woodhouse Lane
LS2 9JT Leeds
United Kingdom

See on map

Region
Yorkshire and the Humber West Yorkshire Leeds
Activity type
Higher or Secondary Education Establishments
Other funding
€ 0,00

Participants (5)

UNIVERSITAETSKLINIKUM ESSEN
Germany
Net EU contribution
€ 747 649,44
Address
Hufelandstrasse 55
45147 Essen

See on map

Region
Nordrhein-Westfalen Düsseldorf Essen, Kreisfreie Stadt
Activity type
Higher or Secondary Education Establishments
Other funding
€ 0,00
LUNDS UNIVERSITET
Sweden
Net EU contribution
€ 790 977,96
Address
Paradisgatan 5c
22100 Lund

See on map

Region
Södra Sverige Sydsverige Skåne län
Activity type
Higher or Secondary Education Establishments
Other funding
€ 0,00
GENOME RESEARCH LIMITED
United Kingdom
Net EU contribution
€ 546 575,76
Address
The Gibbs Building, Euston Road 215
NW1 2BE London

See on map

Region
London Inner London — West Camden and City of London
Activity type
Research Organisations
Other funding
€ 0,00
ACADEMISCH ZIEKENHUIS LEIDEN
Netherlands
Net EU contribution
€ 510 748,56
Address
Albinusdreef 2
2333 ZA Leiden

See on map

Region
West-Nederland Zuid-Holland Agglomeratie Leiden en Bollenstreek
Activity type
Higher or Secondary Education Establishments
Other funding
€ 0,00
OSLO UNIVERSITETSSYKEHUS HF
Norway
Net EU contribution
€ 572 550,48
Address
Kirkeveien 166 Tarnbygget
0450 Oslo

See on map

Region
Norge Oslo og Viken Oslo
Activity type
Higher or Secondary Education Establishments
Other funding
€ 0,00